Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with standard-of-care FLOT chemotherapy demonstrated a statistically ...

Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts across multiple therapeutic areas expected in 2025 ...

AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat. The two companies' relationship around ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

To celebrate the 50th anniversary of the establishment of diplomatic relations between the Philippines and China, the ...

FibroGen sells its China unit to AstraZeneca for about $160M, strengthening its cash position and extending its financial runway into 2027. AstraZeneca gains full rights to roxadustat in China ...

AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...

The Manila International Airport Authority (MIAA) unveiled its new logo during its 43rd Anniversary celebration on Friday.

AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

SUBIC BAY FREEPORT—On any given day, barring only extreme weather conditions, hundreds of visitors venture into this water wonderland to watch spectacular shows. In this place, where the dense ...

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a ...